Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097786
Status:
COMPLETED
Last Update Posted:
2023-11-08
First Post:
2004-11-30
Brief Title:
Long-term Study of NateglinideValsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Multinational Randomized Double-blind Placebo-controlled Forced-titration 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance IGT
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Navigator
Brief Summary:
This study is a test of the safety and effectiveness of two drugs one for diabetes and one for hypertension in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications People in this study cannot have frank diabetes but are considered borderline based on blood tests People in the study take none one or both of the drugs and do not know which ones they are taking
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None